For patients with KRAS G12C non-small cell lung cancer, participation in a clinical trial offers access to next-generation inhibitors that are superior to currently approved agents. This presents a unique situation where standard of care is demonstrably behind investigational therapies.
Unlike other oncogene addictions like EGFR or ALK, KRAS G12C mutations are prevalent in smokers. This biological context means tumors are highly immunosensitive, making immunotherapy (IO) a synergistic and necessary component of treatment, rather than a conflicting one.
The primary challenge with combining next-gen KRAS inhibitors and immunotherapy is a rapid and severe liver toxicity (transaminitis). A patient's liver function can deteriorate catastrophically in days, demanding vigilant monitoring and specific management protocols that differ between clinical trials.
While pan-RAS inhibitors like daroxiracib can target multiple mutations, they cause significantly more GI and skin toxicity. For a homogenous KRAS G12C mutation, a mutant-selective inhibitor is preferred as it offers comparable efficacy with a much more manageable side effect profile, crucial for maintaining dose intensity.
Early data for next-generation KRAS G12C inhibitors combined with immunotherapy shows a doubling of both response rate (to ~75%) and progression-free survival compared to the current standard of chemo-immunotherapy. This dramatic improvement suggests these combinations will rapidly become the new standard of care.
Clinicians avoid combining KRAS inhibitors with immunotherapy before surgery (neoadjuvant) due to the high risk of severe toxicity. Such an adverse event could jeopardize the window for a potentially curative surgery, making the post-surgical (adjuvant) setting the preferred approach for these potent combinations.
In PD-L1 negative KRAS-mutated lung cancer, where standard immunotherapy is less effective, adding a CTLA-4 inhibitor can recover the immune response and create long-term survivors. This makes a triplet or quadruplet regimen the current optimal strategy for this challenging patient subgroup.
There is emerging evidence for sequencing KRAS inhibitors based on their mechanism. The "on-state" inhibitor Eliron-RASIB has shown a 50% response rate in patients previously treated with "off-state" inhibitors like adagrasib, suggesting that the resistance mechanism determines the effectiveness of subsequent therapy.